Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Melody R Becnel, MD
M.D. Anderson Cancer Center
Principal Investigator - Rahul Banerjee, MD
University of Washington
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Active, not recruiting - University of Washington
Seattle, Washington, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Jun 2022
- Primary completion
- 31 Aug 2025
- Completion
- 31 Dec 2025
- Last update posted
- 11 Dec 2024
- Registered enrollment
- 50
- Registry id
- NCT05053607
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.